Marksans Pharma Ltd Analyst Rating
based on 3 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Marksans Pharma Ltd. An average target of ₹330.33
Source: S&P Global Market Intelligence
Marksans Pharma Ltd Share analysis
Marksans Pharma Ltd price forecast by 3 analysts
Upside of4.39%
High
₹376
Target
₹330.33
Low
₹265
Marksans Pharma Ltd target price ₹330.33, a slight upside of 4.39% compared to current price of ₹304.9. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Marksans Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:41.23%
Forecast
Actual
Including amortisation and stock based compensations
Marksans Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:56.50%
Forecast
Actual
Source: S&P Global Market Intelligence
Marksans Pharma Ltd Performance
Day's Low
Day's High
₹276Day's Price Range₹323.4552 Week's Low
52 Week's High
₹13052-Week Price Range₹358.7
| Returns % | |
| 1 Month Return | + 2.36 % |
| 3 Month Return | + 0.61 % |
| 1 Year Return | + 98.84 % |
| Market Stats | |
| Previous Close | ₹316.45 |
| Open | ₹317.00 |
| Volume | 14.72L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹14,503.51Cr |
Marksans Pharma Ltd Key Statistics
| P/E Ratio | 41.31 |
| PEG Ratio | 53.65 |
| Market Cap | ₹14,503.51 Cr |
| P/B Ratio | 5.62 |
| EPS | 6.95 |
| Dividend Yield | 0.4 |
| Sector | Pharmaceuticals |
| ROE | 11.46 |
Marksans Pharma Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹14,503.51 Cr | 355.61% | 0.51 | ₹314 Cr | ₹2,177 Cr | |
| NA | ₹435.76 Cr | 272.24% | 0.54 | ₹28 Cr | ₹601 Cr | |
| NA | ₹15.41 Cr | 278.33% | 0.50 | NA | NA | |
| BUY | ₹23,100.09 Cr | 3.59% | 0.52 | NA | NA | |
| NA | ₹706.49 Cr | -0.07% | 0.57 | ₹9 Cr | ₹179 Cr |
About Marksans Pharma Ltd
Share Price: ₹304.90 per share as on 20 Dec, 2024 04:01 PM
Market Capitalisation: ₹14,503.51Cr as of today
Revenue: ₹641.92Cr as on September 2024 (Q3 24)
Net Profit: ₹97.76Cr as on September 2024 (Q3 24)
Listing date: 21 Jan, 2002
Chairperson Name: Mark Saldanha
| Organisation | Marksans Pharma Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Marksans Pharma Ltd
Marksans Pharma Hits 52-Week High After FDA Approval - 27 Nov, 2024
Marksans Pharma shares surged 4.1% to a 52-week high of ₹351.5, marking a 142% gain over the past year. The rally follows FDA approval for Loratadine Tablets, used for treating allergies. The company also reported a 16% increase in net profit and a 21% rise in revenue for Q2FY25.Marksans Pharma Hits New High on Strong Q2 Results - 26 Nov, 2024
Marksans Pharma's stock surged 30% in a month, reaching a record high of Rs 343.85, driven by strong Q2 results with a 20.8% revenue growth and 16.6% profit increase. The company received USFDA approval for Loratadine Tablets, further boosting its outlook.Marksans Pharma Secures USFDA Approval for Allergy Drug - 22 Nov, 2024
Marksans Pharma Ltd has received final USFDA approval for its Loratadine tablets, enhancing its portfolio in allergy treatments. The stock rose 3.2% following the announcement.Marksans Pharma Reports Strong Q3 Growth - 13 Nov, 2024
Marksans Pharma's standalone net sales for September 2024 reached Rs 308.63 crore, up 50.79% YoY. Net profit surged 102% to Rs 63.20 crore, with EBITDA rising 57.11%. The stock has delivered impressive returns of 92.63% over the last six months and 118.07% over the past year.Marksans Pharma Reports Strong Q2 FY25 Financials - 12 Nov, 2024
Marksans Pharma's Q2 FY25 results show significant growth, with revenue rising 20.84% YoY to Rs 641.92 crore and net profit increasing 16.56% YoY. The stock gained 2.70% following the announcement, reflecting positive investor sentiment.
Insights on Marksans Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 2.82% to 3.02% in Sep 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, MARKSANS stock has moved up by 102.7%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 78.29 Cr → 96.72 Cr (in ₹), with an average increase of 10.0% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 576.54 Cr → 652.98 Cr (in ₹), with an average increase of 6.0% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 7.71% to 10.43% in Sep 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 43.87% of holdings in Sep 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 33.78% to 30.71% in Sep 2024 quarter
Marksans Pharma Ltd Financials
Index Inclusions
Marksans Pharma Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 43.87% | 0.00 | |
| Foreign Institutions | 10.43% | 35.16 | |
| Mutual Funds | 3.02% | 7.44 | |
| Retail Investors | 30.71% | ||
| Others | 11.96% | 1.24 |
Marksans Pharma Ltd Key Indicators
Marksans Pharma Ltd Valuation
Marksans Pharma Ltd in the last 5 years
Lowest (4.67x)
April 1, 2020
Today (41.31x)
December 19, 2024
Industry (56.23x)
December 19, 2024
Highest (46.60x)
January 24, 2018
Marksans Pharma Ltd Earnings and Dividends
Marksans Pharma Ltd Earnings Results
Marksans Pharma Ltd’s net profit jumped 15.8% since last year same period to ₹96.72Cr in the Q2 2024-2025. On a quarterly growth basis, Marksans Pharma Ltd has generated 8.98% jump in its net profits since last 3-months.
Read More about Earnings ResultsMarksans Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Marksans Pharma Ltd has declared dividend of ₹0.60 - translating a dividend yield of 0.36%.
Read More about Dividends
Marksans Pharma Ltd Technicals Summary
Bearish
Neutral
Bullish
Marksans Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Marksans Pharma Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Marksans Pharma Ltd shares.
Marksans Pharma Ltd (MARKSANS) share price today is ₹304.9
Marksans Pharma Ltd is listed on NSE
Marksans Pharma Ltd is listed on BSE
- Today’s highest price of Marksans Pharma Ltd is ₹323.45.
- Today’s lowest price of Marksans Pharma Ltd is ₹276.
PE Ratio of Marksans Pharma Ltd is 41.31
PE ratio = Marksans Pharma Ltd Market price per share / Marksans Pharma Ltd Earnings per share
Today’s traded volume of Marksans Pharma Ltd(MARKSANS) is 14.72L.
Today’s market capitalisation of Marksans Pharma Ltd(MARKSANS) is ₹14503.51Cr.
| Marksans Pharma Ltd(MARKSANS | Price |
|---|---|
52 Week High | ₹358.7 |
52 Week Low | ₹130 |
Marksans Pharma Ltd(MARKSANS) share price is ₹304.9. It is down -15.00% from its 52 Week High price of ₹358.7
Marksans Pharma Ltd(MARKSANS) share price is ₹304.9. It is up 134.54% from its 52 Week Low price of ₹130
| Marksans Pharma Ltd(MARKSANS | Returns |
|---|---|
1 Day Returns | -11.55% |
1 Month Returns | 2.36% |
3 Month Returns | 0.61% |
1 Year Returns | 98.84% |